- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06389019
Hele dia-afbeelding en op CT-radiomics gebaseerd diep leersysteem voor prognosevoorspelling bij blaaskanker
Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA.This observational study evaluates a deep learning system that combines CT images and digitized pathology slides to predict outcomes in patients with bladder cancer. It includes a retrospective cohort and a prospective cohort of newly enrolled patients. The prospective cohort will assess the system in patients enrolled during (2024-2026), with follow-up for survival and recurrence.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Study structure The study includes an initial retrospective phase and a subsequent prospective observational phase involving newly enrolled patients. The two phases are analyzed separately according to the specified analysis plan.
Retrospective phase The retrospective phase included patients from [2012-2024] and was used for model construction. Results from this phase were reported in npj series.
Prospective phase Enrollment of newly recruited patients began on [2024]. The prospective phase follows protocol, with ethics approval from the first affliated hospital of chongqing medical, university. Recruitment is consecutive, as specified in the protocol.
Model evaluation The prospective cohort is used for validation. The model version, preprocessing procedures and prediction thresholds used in this phase. Any model updating using this cohort is documented separately.
Registry update This update distinguishes the retrospective phase from the subsequently enrolled cohort. The prospective phase enrollment dates and the dates of protocol development and ethics approval are reported separately.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: QuanHao He
- Telefoonnummer: 800-555-5555
- E-mail: 2020120460@stu.cqmu.edu.cn
Studie Contact Back-up
- Naam: Mingzhao Xiao, PHD
- Telefoonnummer: 800-555-5555
- E-mail: 2023140134@stu.cqmu.edu.cn
Studie Locaties
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Werving
- Department of Urology, The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- QuanHao He, PHD
- Telefoonnummer: 800-555-5555
- E-mail: 2020120460@stu.cqmu.edu.cn
-
Contact:
- Mingzhao Xiao, PHD
- Telefoonnummer: 023-89012557
- E-mail: 2023140134@stu.cqmu.edu.cn
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
We included patients who had surgery only or who had neoadjuvant chemotherapy before surgery. We excluded patients with a postoperative diagnosis of non-urothelial carcinoma.
Beschrijving
Inclusion Criteria:
- patients with bladder cancer who had surgery like radical cystectomy or transurethral resection of bladder tumour (TURBT)
- contrast-CT scan less than two weeks before surgery
- complete CT image data and clinical data
- complete whole slide image data
Exclusion Criteria:
- patients with a postoperative diagnosis of non-urothelial carcinoma
- poor quality of CT images
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: OTHER
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Retrospective cohort
Patients with bladder cancer included in the retrospective phase of the study, using clinical records, CT images, and whole-slide images obtained during [2012-2024]. This cohort was used for model development and/or validation and was reported in our npj publications. |
develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images. |
|
Prospective cohort of newly enrolled patients
Newly enrolled patients with bladder cancer recruited at four centers between 2024 and2026. Eligibility is assessed at enrollment, and participants are followed according to protocol version and date for the study outcomes. This cohort is distinct from the previously reported retrospective cohort. |
develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival
Tijdsspanne: up to 10 years
|
the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off. |
up to 10 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recurrence free survival
Tijdsspanne: up to 10 years
|
the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored |
up to 10 years
|
|
progression-free survival
Tijdsspanne: up to 10 years
|
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works. Also called PFS. |
up to 10 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Urologische neoplasmata
- Ziekten van de urineblaas
- Neoplasmata van de urineblaas
Andere studie-ID-nummers
- BLCA_CMUFH
- K2024-187-01 (Andere identificatie: The First Affiliated Hospital of Chongqing Medical University)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The datasets analyzed during the current study are not publicly available due to the privacy of patients but are available from the corresponding author on reasonable request.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .